Article
Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results.
Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 May 2018
Moreno-Grau Sonia, Rodríguez-Gómez Octavio, Sanabria Ángela, Pérez-Cordón Alba, Sánchez-Ruiz Domingo, Abdelnour Carla, Valero Sergi, Hernández Isabel, Rosende-Roca Maitée, Mauleón Ana, Vargas Liliana, Lafuente Asunción, Gil Silvia, Santos-Santos Miguel Ángel, Alegret Montserrat, Espinosa Ana, Ortega Gemma, Guitart Marina, Gailhajanet Anna, de Rojas Itziar, Sotolongo-Grau Óscar, Ruiz Susana, Aguilera Nuria, Papasey Judith, Martín Elvira, Peleja Esther, Lomeña Francisco, Campos Francisco, Vivas Assumpta, Gómez-Chiari Marta, Tejero Miguel Ángel, Giménez Joan, Serrano-Ríos Manuel, Orellana Adelina, Tárraga Lluís, Ruiz Agustín, Boada Mercè
Abstract excerpt
INTRODUCTION: Subjective cognitive decline (SCD) has been proposed as a potential preclinical stage of Alzheimer's disease (AD). Nevertheless, the genetic and biomarker profiles of SCD individuals remain mostly unexplored. METHODS: We evaluated apolipoprotein E (APOE) ε4's effect in the risk of presenting SCD, using the Fundacio ACE Healthy Brain Initiative (FACEHBI) SCD cohort and Spanish controls, and performed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.